Clinical trials
Lung Cancer Patients clinical trials
Below are recruiting lung cancer patients clinical trials, each written for real people, not researchers. We’re tracking 1,877 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07130786RecruitingPhase 2
Preventing seizures with medication for brain tumors in movement area
This study tests whether giving a seizure medication (levetiracetam) to people with brain tumors in the movement area can prevent seizures. It compares taking the medication to not taking it, starting before any seizure occurs.
Boston, MassachusettsAges 18 years+ - NCT07279935RecruitingPhase 4
Osimertinib plus chemotherapy for lung cancer that returned after osimertinib
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
BeijingAges 18 years+ - NCT07120282RecruitingPhase 2
Tislelizumab after surgery for early-stage lung cancer
This trial tests whether a drug called tislelizumab, given after surgery, can help prevent lung cancer from coming back. It is for people with stage I non-small cell lung cancer who have certain high-risk features and a protein called PD-L1 on their tumor cells.
BeijingAges 18 years+ - NCT04428554RecruitingPhase 2
Radiation to control bladder cancer spread after no growth
This trial tests whether giving focused radiation (SBRT) to a few remaining metastatic spots can stop bladder cancer from progressing after initial chemotherapy or immunotherapy has worked. It may help patients who still have up to three remaining distant lesions but are not getting worse.
AlbiAges 18 years+ - NCT07264816RecruitingPhase 2
Study of BL-M07D1 and Pembrolizumab for HER2+ Lung Cancer
This study tests a new drug combination, BL-M07D1 plus pembrolizumab (an immunotherapy), for people with a certain type of advanced lung cancer that has high levels of HER2 protein. The goal is to see if the combination is safe and effective for people who have not been treated with HER2-targeting drugs before.
Wuhan, HubeiAges 18–75 - NCT05473156RecruitingPhase 1/Phase 2
Study of AP203 for advanced solid tumors that grew despite treatment
This early-phase study tests AP203 (an investigational treatment) to see if it is safe and to look for signs it can shrink or control certain advanced cancers. The study includes a dose-finding part for many solid tumors, and a second part focused on specific lung and head/neck cancers that previously received PD-1/PD-L1 therapy.
TaipeiAges 18 years+ - NCT06457906RecruitingPhase 3
Focused radiation vs whole brain radiation for up to 10 lung cancer brain spots
This trial compares two types of radiation for people with small cell lung cancer that has spread to the brain (10 or fewer spots). One approach uses focused radiation only on the tumors, the other treats the whole brain while trying to protect memory. The goal is to see which works better with fewer side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT07373951Enrolling by invitation
Predicting cancer gene status from MRI scans in brain metastasis
This trial uses brain MRI scans and deep learning to predict whether non-small cell lung cancer that has spread to the brain has certain gene changes (EGFR or ALK). Knowing this may help guide treatment without needing additional tissue testing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04996121RecruitingPhase 1/Phase 2
Drug for tumors with NTRK or ROS1 gene fusions
This trial studies an investigational pill (XZP-5955) for solid tumors that have specific gene changes: NTRK or ROS1 fusions. It is meant for people whose cancer is advanced or has spread, and who may not have good standard treatment options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07559786RecruitingPhase 2
Adebrelimab after chemo-radiation for limited-stage small cell lung cancer
This trial tests whether the drug adebrelimab (a type of immunotherapy) can help prevent your lung cancer from coming back after you finish chemotherapy and radiation. It is for people with limited-stage small cell lung cancer (cancer found only in one lung and nearby lymph nodes) that did not grow during initial treatment.
Zhengzhou, HenanAges 18–75 - NCT07195695RecruitingPhase 3
Zongertinib after surgery for HER2-mutated lung cancer
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Fresno, CaliforniaAges 18 years+ - NCT06762405RecruitingPhase 3
Testing dostarlimab with short radiation for MSI rectal cancer
This trial tests a new approach: giving the immunotherapy drug dostarlimab along with a short course of radiation before surgery, with the goal of avoiding surgery in many patients. It is for people with a specific type of rectal cancer (MSI-H or dMMR) that has not spread to other organs.
DijonAges 18 years+ - NCT06907160Recruiting
Genetic testing before lung cancer treatment
This study looks at how tumors respond to chemotherapy plus immunotherapy before surgery for non-small cell lung cancer. It uses genetic tests on the tumor and blood to personalize treatment and possibly improve outcomes.
SeoulAges 19 years+ - NCT06385262RecruitingPhase 2
Chemo before surgery for early-stage lung cancer
This study tests whether giving chemotherapy before surgery helps people with non-small cell lung cancer that has not spread far. The goal is to see if it can shrink the tumor and improve outcomes.
Durham, North CarolinaAges 18 years+ - NCT07874490RecruitingPhase 2
Osimertinib plus cyclosporine for advanced lung cancer
This study tests whether adding cyclosporine to the standard drug osimertinib can make it work better in people with advanced non-small cell lung cancer that has a specific EGFR gene change. You can join even if you haven't started treatment or have just started osimertinib within the last 3 weeks.
New York, New YorkAges 18 years+ - NCT04286841Recruiting
Immunotherapy before lung surgery for early lung cancer
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
Guangzhou, GuangdongAges 18 years+ - NCT04905056RecruitingPhase 2
Ablation treatment for lung ground-glass nodules that don’t go away
This Phase 2 trial studies whether a procedure called “ablation” is safe and effective for certain lung cancers that appear as ground-glass spots on CT scans and do not improve after 3 months. It may help people who cannot fully have surgery for their condition.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT05172739RecruitingPhase 4
Opioid-free anesthesia during lung surgery for early lung cancer
This study tests whether an opioid-free pain/anesthesia plan during elective lung surgery can reduce surgical “stress” on the body and affect the immune system. You may be eligible if you have early-stage non-small cell lung cancer and are scheduled for a specific type of surgery (VATS lobectomy).
Heraklion, CreteAges 18–80 - NCT02354274Recruiting
New radiation approach for locally advanced lung cancer
This study tests a new way of giving radiation for people with locally advanced non-small cell lung cancer (NSCLC), along with a chemotherapy medicine (navelbine). It may help by improving how well the treatment controls the cancer in the chest while watching for side effects.
AalborgAges 18 years+ - NCT05366478RecruitingPhase 1
LM103 for advanced solid tumors using donated immune cells
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
TianjinAges 18 years+ - NCT04875585RecruitingPhase 2
Neoadjuvant and post-surgery immunotherapy for operable lung cancer
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
Innsbruck, TyrolAges 18 years+ - NCT05334277RecruitingPhase 2
Test furmonertinib for advanced EGFR-mutant lung cancer
This Phase 2 trial studies furmonertinib alone or with other treatment options to control advanced lung cancer that has specific EGFR gene changes. It may help by targeting the cancer-driving EGFR mutation, especially in people whose mutation is confirmed by a ctDNA blood test.
ChangchunAges 18 years+ - NCT05429463RecruitingPhase 3
Surgery-ready lung cancer treatment with immunotherapy plus chemo
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
Hangzhou, ZhejiangAges 18–75 - NCT04677205Recruiting
Tumor-to-lymph-node study after lung cancer surgery
This study looks at molecular (biologic) signals in the tumor and nearby lymph nodes after curative surgery for stage IIIA lung cancer. It may help doctors better understand the disease and improve future treatment planning.
BordeauxAges 18 years+
Hear when a new Lung Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer patients?
- Yes. Clin2 currently lists 1,877 recruiting lung cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.